Chimerix, Inc. entered into a Supply Agreement with a third party outside of North America (the “Purchaser”), pursuant to which the Company is responsible for supplying to the Purchaser, and the Purchaser is responsible for purchasing from the Company, TEMBEXA (brincidofovir) treatment courses for use outside of the United States. TEMBEXA is a medical countermeasure for smallpox approved by the U.S. Food and Drug Administration in June 2021. Under the terms of the Supply Agreement, the Purchaser has agreed to pay the Company an aggregate purchase price of approximately $9.3 million, to be made in two equal installments.

The first installment is payable upon execution of the Supply Agreement, and the second installment will be payable upon delivery of the treatment courses, as described in the Supply Agreement. Unless earlier terminated, the term of the Supply Agreement continues until the delivery of the TEMBEXA treatment courses under the Supply Agreement is complete. The Company and the Purchaser each have normal and customary termination rights, including termination for material breach that is not cured within a specific timeframe.

Additionally, the Company and the Purchaser each have the right to terminate the Supply Agreement, subject to certain limitations. Additionally, on June 23, 2022, the Public Health Agency of Canada (“PHAC”) awarded a Contract (the “PHAC Contract”) to the Company, pursuant to which PHAC will purchase up to approximately CAD $33.0 million (USD $25.3 million) of TEMBEXA treatment courses for use in Canada. The term of the PHAC Contract continues until the deliveries of the TEMBEXA treatment courses under the PHAC Contract are complete.

References to “CAD” are to the Canadian dollar. The U.S. dollar equivalents listed above in this paragraph were calculated based on an exchange rate of CAD 1.00 to USD 0.7695 as of the close of business on June 23, 2022.